exhibit 10. 5 license agreement between : the university of british columbia, a corporation continued under the university act of british columbia and having its administrative offices at 2075 wesbrook mall, in the city of vancouver, in the province of british columbia, v6t 1w5 ( the “ university ” ) and : xenon genetics inc., a corporation continued under the laws of canada, and having its administrative offices at suite 100 — 2386 east mall, vancouver, british columbia, v6t 1z3 ( the “ licensee ” ) whereas : a. the university has been engaged in research during the course of which it has invented, developed and / or acquired certain technology identified in ubc invention disclosure file # ubc 94 - 061, entitled “ lipolipase mutation 291, implication for coronary artery disease ”, and file # ubc 91 - 003, entitled “ mutation in human lipoprotein lipase gene which causes type 1 hyperlipoproteinemia ” ; b. [ † ] has invented, developed and / or acquired certain technology which may have common subject matter with certain technology invented, developed and / or acquired by the university, and identified in ubc invention disclosure file # ubc 99 - 082, entitled “ recombinant viruses preparation and use thereof in gene therapy ; c. the university has been jointly engaged in research with the academic hospital at the university of amsterdam ( “ amc ” ) during the course of which they have jointly invented, developed and / or acquired certain technology identified in ubc invention disclosure file # ubc 00039, entitled “ mutation 447 ” ; d. the research done at the university with respect to the above referenced technologies was undertaken by dr. michael hayden who is an employee of the university engaged in a number of research projects and a founder and chief scientific officer of the licensee ; e. [ † ] f. the university is desirous of entering into this agreement ( the “ agreement ’ ) with the objective of furthering society ’ s use of its advanced technology, and to generate further research in a manner consistent with its status as a non - profit, tax exempt educational institution ; and [ † ] designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the commission g. subject to the terms and conditions hereinafter set out, the licensee is desirous of the university granting a license to the licensee to